iRadimed Corp. (NASDAQ:IRMD) shares were down 4.7% on Wednesday . The company traded as low as $20.21 and last traded at $20.46, with a volume of 54,478 shares trading hands. The stock had previously closed at $21.48.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of iRadimed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Roth Capital decreased their target price on shares of iRadimed Corp. from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, April 4th.

The firm has a 50-day moving average price of $20.43 and a 200-day moving average price of $18.98. The firm has a market cap of $222.80 million and a price-to-earnings ratio of 30.60.

iRadimed Corp. (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, April 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. The firm had revenue of $8.96 million for the quarter, compared to analyst estimates of $9.05 million. The company’s revenue was up 28.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 earnings per share. On average, equities research analysts predict that iRadimed Corp. will post $0.89 earnings per share for the current fiscal year.

In other iRadimed Corp. news, Director Monty K. Allen sold 2,100 shares of the company’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $20.44, for a total transaction of $42,924.00. Following the transaction, the director now directly owns 4,375 shares in the company, valued at $89,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Monty K. Allen sold 2,275 shares of the company’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $20.00, for a total transaction of $45,500.00. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently modified their holdings of the company. GSA Capital Partners LLP raised its position in shares of iRadimed Corp. by 174.3% in the fourth quarter. GSA Capital Partners LLP now owns 50,203 shares of the company’s stock valued at $1,407,000 after buying an additional 31,901 shares during the last quarter. AWM Investment Company Inc. raised its position in shares of iRadimed Corp. by 79.2% in the fourth quarter. AWM Investment Company Inc. now owns 278,330 shares of the company’s stock valued at $7,802,000 after buying an additional 123,000 shares during the last quarter. EAM Investors LLC raised its position in shares of iRadimed Corp. by 0.4% in the fourth quarter. EAM Investors LLC now owns 78,945 shares of the company’s stock valued at $2,213,000 after buying an additional 311 shares during the last quarter. Finally, Russell Frank Co bought a new position in shares of iRadimed Corp. during the fourth quarter valued at $2,675,000.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.